Orthocell Prepares for U.S. Launch of Remplir™

Orthocell Ltd (AU:OCC) has released an update.

Orthocell Ltd is gearing up for a significant entry into the $1.6 billion U.S. nerve repair market with its FDA 510(k) application to distribute Remplir™, a revolutionary nerve repair product. The company anticipates regulatory clearance by early 2025 and is already preparing for a commercial launch with a strong financial position and a dedicated U.S. sales team. With Remplir’s proven success in other markets, this move represents a promising growth opportunity for Orthocell.

For further insights into AU:OCC stock, check out TipRanks’ Stock Analysis page.